CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Stephen Hoge

President, Moderna

Search every verified Stephen Hoge interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. During Moderna’s Q3 2025 earnings call, Hoge reported that the company reduced its projected 2025 cash costs by approximately $500 million since August 2025 and by about $900 million since the beginning of the year. He noted a $2.1 billion improvement in costs across cost of goods, SG&A, and R&D over the prior four quarters. Hoge stated that the company had positive Phase 3 flu efficacy data for its mRNA-1010 program and the flu-COVID combination program mRNA-1083. He also announced that Moderna’s CMV vaccine program did not meet its primary efficacy endpoint for congenital CMV and would be discontinued in that indication. In oncology, he highlighted encouraging Phase 1b data for the cancer antigen therapy mRNA-4359, presented at the European Society of Medical Oncology Congress. In media appearances, Hoge discussed Moderna’s next-generation COVID vaccine candidate, which he described as not containing the full spike protein and being administered at a lower dose. He said the company had not seen signals of myocarditis or pericarditis in clinical trials for that candidate. Hoge expressed that he wished the company had emphasized more that the pandemic would require a longer-term, evolving relationship with the virus. He stated that Moderna is running a large Phase 3 trial in melanoma skin cancer expected to read out in 2026)Skip, and that the company must engage with regulators in the U.S., Canada, Japan, and Europe to determine the standard of care for pivotal trials. He acknowledged challenges in public trust and said the company aims to use science and transparent communication to address public health threats.

Recent appearances

Other executives at Moderna

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →